Select Language
BCMA
BCMA Overview
| English Name | B-cell maturation protein | Approved Drugs | 7 |
| Drugs in Clinical Trials | 120 | Target Synonym | B-Cell Maturation Protein，B-Cell Maturation Factor，B Cell Maturation Antigen，CD269 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 17，TNFRSF17，TNFRSF13A，CD269，BCM，BCMA，TNF Receptor Superfamily Member 17，Tumor Necrosis Factor Receptor Superfamily， Member 17，B-Cell Maturation Antigen |
| Highest Development Stage | Approved | ||
| English Name | B-cell maturation protein |
| Target Synonym | B-Cell Maturation Protein，B-Cell Maturation Factor，B Cell Maturation Antigen，CD269 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 17，TNFRSF17，TNFRSF13A，CD269，BCM，BCMA，TNF Receptor Superfamily Member 17，Tumor Necrosis Factor Receptor Superfamily， Member 17，B-Cell Maturation Antigen |
| Approved Drugs | 7 |
| Drugs in Clinical Trials | 120 |
| Highest Development Stage | Approved |
BCMA Product List
- Product Category
Protein (31)Antibody (1)Beads (1)Cell Grade Beads (1)Kits (1)Cell (2)
- Product Status
Launched (38)
- Species
Human (25)Cynomolgus / Rhesus macaque (5)Mouse (4)Rabbit (1)Rat (1)Canine (1)
- Tag
Fc Tag (4)His Tag (19)Fc Tag & Avi Tag (3)Llama IgG Fc Tag (2)His Tag & Avi Tag (2)Mouse IgG Fc Tag (1)Mouse IgG1 (1)- (6)
- Conjugate
Unconjugated (17)FITC Labeled (3)Biotin-labeled (5)- (6)PE Labeled (2)APC Labeled (2)AF488 Labeled (1)AF647 Labeled (1)AF555 Labeled (1)
Total: 37
- 1
- 2
- 3
- 4
BCMA Background
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.
BCMA Synonyms
TNFRSF17,CD269,BCM,BCMA
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| BCMA VHH - 01 | Lead | Monoclonal | Nanobody | Hematological Malignancy | Multiple myeloma |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) | Phase 3 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia; Multiple Myeloma | Details | |
| Anitocabtagene autoleucel | Kite-772; CART-ddBCMA | Phase 3 Clinical | Arcellx Inc | Myasthenia Gravis; Neuromuscular Manifestations; Autoimmune Diseases; Multiple Myeloma; Muscular Diseases; Muscle Weakness; Autoimmune Diseases of the Nervous System | Details |
| CD3 and B-cell maturation antigen T-cell engaging bispecific antibody (AbbVie/TeneoOne) | ABBV-383; TNB-383B | Phase 3 Clinical | TeneoOne Inc | Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma | Details |
| Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) | Descartes-08 | Phase 3 Clinical | Cartesian Therapeutics Inc | Myasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic | Details |
| BCMA CAR-T Cells (Pregene) | PRG-1801; GLPG-5301; DRL-1801 | Phase 2 Clinical | Purpura, Thrombocytopenic, Idiopathic; Immunoglobulin G4-Related Disease; Multiple Myeloma; Lupus Nephritis | Details | |
| Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) | BCMA-CART; HR003 | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Multiple Myeloma | Details |
| Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Lymphoma, B-Cell; Multiple Myeloma; Lymphoma, Non-Hodgkin | Details | |
| BCMA CAR-T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell | Details | |
| C-CAR088 | C-CAR088 | Phase 2 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Multiple Myeloma | Details |
| Orvacabtagene autoleucel | ET-140; FCARH-143; ET140-CAR; MCARH-171; JCARH-125 | Phase 2 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
| GC-012F | GC-012F; GC012F; AZD-0120; AZD0120 | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Myasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin | Details |
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
| KQ-2003 | KQ-2003; KQ2003 | Phase 2 Clinical | Shanghai Keqi Pharmaceutical Technology Co Ltd | Solid tumours; Multiple Myeloma; POEMS Syndrome | Details |
| HDP-101 | HDP-101; HDP101-ATAC | Phase 2 Clinical | Heidelberg | Hematologic Diseases; Paraproteinemias; Multiple Myeloma | Details |
| REGN-5459 | REGN-5459 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital) | Phase 2 Clinical | Peking University People'S Hospital | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Immunoglobulin G4-Related Disease; Sjogren's Syndrome; Scleroderma, Systemic; Antiphospholipid Syndrome; Lupus Erythematosus, Systemic; Acquired thrombotic thrombocytopenic purpura; Behcet Syndrome | Details | |
| anti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Multiple Myeloma | Details | |
| BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Multiple Myeloma | Details | |
| Chimeric Antigen Receptor Modified T Cells Targeting BCMA(The First Affiliated Hospital of Xiamen University) | Phase 2 Clinical | The First Affiliated Hospital Of Xiamen University | Hematologic Neoplasms; Multiple Myeloma | Details | |
| BCD-248 | BCD-248 | Phase 2 Clinical | BIOCAD JSC | Multiple Myeloma | Details |
| Nanobody-based biepitope BCMA-targeting CAR-T cells therapy(Tahoe Chunyu Biotechnology) | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Multiple Myeloma | Details | |
| CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of Health | Plasmacytoma; Multiple Myeloma | Details | |
| Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech) | Phase 2 Clinical | Essen Biotech | Granulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Microscopic Polyangiitis; Myositis; Scleroderma, Systemic; Autoimmune Diseases; Sjogren's Syndrome; Lupus Nephritis; Lupus Erythematosus, Systemic | Details | |
| Anti-BCMA CAR-NK Therapy(Shahid Beheshti University of Medical Sciences) | Phase 2 Clinical | Shahid Beheshti University Of Medical Sciences | Multiple Myeloma | Details | |
| IBI-3003 | IBI3003; IBI-3003 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Multiple Myeloma | Details |
| BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene) | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Multiple Myeloma | Details | |
| CART-ASCT-CART2 cells Therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Multiple Myeloma | Details | |
| MBS-314 | MBS-314 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Multiple Myeloma | Details |
| SAR445514 | SAR445514; SAR-445514; IPH6401/SAR'514 | Phase 2 Clinical | Sanofi | Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma | Details |
| CART-BCMA(Simnova) | SNC-102(Simnova); SNC102(Simnova) | Phase 2 Clinical | Shanghai Simnova Biotechnology Co Ltd | Multiple Myeloma | Details |
| Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Shanghai YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| CAR-BCMA(Sheba Medical Center) | Phase 2 Clinical | Sheba Medical Center, Israel | Multiple Myeloma | Details | |
| ARI-0002h | ARI-0002h | Phase 2 Clinical | Instituto De Salud Carlos Iii | Multiple Myeloma | Details |
| Descartes-11 | Descartes-11; Descartes-011 | Phase 2 Clinical | Cartesian Therapeutics Inc | Multiple Myeloma | Details |
| BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Multiple Myeloma | Details | |
| GR-1803 | GR-1803 | Phase 2 Clinical | Chongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Multiple Myeloma | Details |
| CM-336(Connaught Biomedical Technology) | CM-336; OM336 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Purpura, Thrombocytopenic, Idiopathic; Multiple Myeloma | Details |
| PHE-885 | PHE-885 | Phase 2 Clinical | Novartis Pharma Ag | Hematologic Neoplasms; Multiple Myeloma | Details |
| Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) | Phase 2 Clinical | Shandong New Time Pharmaceutical Co Ltd | Multiple Myeloma | Details | |
| EMB-06 | EMB-06; EMB06; CN106; CND106; CND-106 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Multiple Myeloma; Pemphigus | Details |
| NXC-201 | HBI-0101; NXC-201 | Phase 2 Clinical | Hadassah Medical Organization, Immix Biopharma Inc | Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma | Details |
| BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Neoplasms; Multiple Myeloma | Details | |
| BCMA TriTAC | HPN-217 | Phase 1 Clinical | Harpoon Therapeutics, Abbvie Inc | Multiple Myeloma | Details |
| ACTR 087/SEA BCMA combination therapy | Phase 1 Clinical | Unum Therapeutics Inc | Multiple Myeloma | Details | |
| bb-21217 | bb-21217 | Phase 1 Clinical | Bluebird Bio Inc, Bristol-Myers Squibb Company | Multiple Myeloma | Details |
| AMG-224 | AMG-224 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| Ispectamab debotansine | CC-99712; BMS-986352; SP-8919 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
| Pacanalotamab | AMG-420; BI-836909 | Phase 1 Clinical | Micromet Inc | Multiple Myeloma | Details |
| ALLO-715 | ALLO-715 | Phase 1 Clinical | Cellectis Sa | Multiple Myeloma | Details |
| Alnuctamab | CC-93269; EM-901; BMS-986349 | Phase 1 Clinical | Engmab Ag | Multiple Myeloma | Details |
| Pavurutamab | AMG-701 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| CART-BCMA | MTV-273; CART-BCMA | Phase 1 Clinical | University Of Pennsylvania | Rejection of renal transplantation; Renal Insufficiency; Multiple Myeloma; Kidney Failure, Chronic | Details |
| BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Multiple Myeloma; Lupus Erythematosus, Systemic; Pancytopenia; Waldenstrom Macroglobulinemia | Details | |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
| DXC-009 | DXC-009 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Multiple Myeloma | Details |
| Descartes-15 | Descartes-015; Descartes-15 | Phase 1 Clinical | Cartesian Therapeutics Inc | Solid tumours; Multiple Myeloma; Autoimmune Diseases of the Nervous System | Details |
| ACLX-001 | ACLX-001 | Phase 1 Clinical | Arcellx Inc | Multiple Myeloma | Details |
| CB-011 | CB-011 | Phase 1 Clinical | Caribou Biosciences Inc | Multiple Myeloma | Details |
| FT-576 | FT-576 | Phase 1 Clinical | University Of Minnesota, Fate Therapeutics Inc | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| P-BCMA-ALLO1 | P-BCMA-ALLO1; RG-6538 | Phase 1 Clinical | Janssen Biotech Inc, Transposagen Biopharmaceuticals Inc | Multiple Myeloma | Details |
| Anti-CD19/BCMA CAR NK cells therapy(The Children's Hospital of Zhejiang University School of Medicine) | KN5601; KN-5601 | Phase 1 Clinical | The Children'S Hospital, Zhejiang University School Of Medicine | Nephrosis; Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |
| RD06-05 | RD06-05 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica; Lupus Erythematosus, Systemic | Details |
| Universal allogeneic anti-CD19/BCMA CAR T-cells therapy(XiNiao Biotechnology) | Phase 1 Clinical | Hangzhou XiNiao Biotechnology Co Ltd | Anemia, Hemolytic, Autoimmune | Details | |
| 68Ga-BC1 | 68Ga-BC1 | Phase 1 Clinical | The First Affiliated Hospital Of Beijing University | Multiple Myeloma; Neoplasms, Plasma Cell | Details |
| UF-KURE-BCMA CAR-T Cells therapy(University Hospitals Cleveland Medical Center) | Phase 1 Clinical | University Hospitals Cleveland Medical Center | Multiple Myeloma | Details | |
| ESO-T01 | ESO-T01 | Phase 1 Clinical | Multiple Myeloma | Details | |
| REVO-UWD-00B | REVO-UWD-00B; UWD-00B | Phase 1 Clinical | Wondercel Therapeutics Co Ltd | Multiple Myeloma | Details |
| Anti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine) | Phase 1 Clinical | The Children'S Hospital, Zhejiang University School Of Medicine | Nephrosis | Details | |
| PRG-2311 | PRG-2311 | Phase 1 Clinical | Immunoglobulin G4-Related Disease; Lupus Nephritis | Details | |
| BZE-2204 | BZE2204; BZE-2204 | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Lymphoma, B-Cell; Multiple Myeloma | Details |
| OL-101 | OL-101 | Phase 1 Clinical | Overland Pharmaceuticals (Shanghai) Co Ltd | Multiple Myeloma | Details |
| Anti-CD19/BCMA CAR T-cell therapy(YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Lupus Nephritis; Lupus Erythematosus, Systemic | Details | |
| Zirconium-89 belantamab | 89Zr-GSK2857914 | Phase 1 Clinical | Glaxosmithkline Plc | Neoplasms; Multiple Myeloma | Details |
| RD-140 | RD140 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| BCMA CAR-NK (Hrain Biotechnology) | HR012 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| CD19/BCMA Hi-TCR-T cell therapy(Wuhan Union Hospital) | Phase 1 Clinical | Wuhan Union Hospital | Lupus Erythematosus, Systemic | Details | |
| SYS-6020 | SYS6020; SYS-6020 | Phase 1 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Myasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic | Details |
| The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine) | FKC-288; FKC288 | Phase 1 Clinical | Nanjing University School Of Medicine | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Immunoglobulin G4-Related Disease; Lupus Nephritis | Details |
| YKST-02 | YKST02; YKST-02 | Phase 1 Clinical | Excyte Biopharma Ltd | Multiple Myeloma | Details |
| C-CAR168 CAR T-cell therapy (AbelZeta) | C-CAR168 | Phase 1 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Autoimmune Diseases; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Muscular Diseases | Details |
| BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) | BMS-986453 | Phase 1 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
| SIM-0500 | SIM0500; SIM-0500 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering) | Phase 1 Clinical | Hualan Genetic Engineering (Henan) Co Ltd | Multiple Myeloma | Details | |
| BCMA Targeted CAR-T Cell Therapy (Carbiogene Therapeutics) | CBG-002 CAR-T | Phase 1 Clinical | Carbiogene Therapeutics Co Ltd | Multiple Myeloma | Details |
| BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma) | SWK001; SWK-001 | Phase 1 Clinical | Hunan Siweikang Pharmaceutical Co Ltd | Multiple Myeloma | Details |
| Anti-BCMA CAR T (Nanjing Kati Medical Technology) | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Multiple Myeloma | Details | |
| Belantamab | GSK2857914; GSK-2857914 | Phase 1 Clinical | Glaxosmithkline Plc | Autoimmune Diseases; Multiple Myeloma | Details |
| Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) | Phase 1 Clinical | Eugia Pharma Specialities Ltd, Actavis Inc | Multiple Myeloma | Details | |
| LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co) | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Multiple Myeloma | Details | |
| Universal BCMA-CD19 CART cell therapy(BRL Medicine) | BRL-302 | Phase 1 Clinical | BRL Medicine Inc | Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Solid tumours; Autoimmune Diseases; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Prostatic Neoplasms | Details |
| TQB-2934 | TQB2934; TQB-2934 | Phase 1 Clinical | Multiple Myeloma | Details | |
| MCARH-125 | MCARH-125 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details |
| ISB-2001 | ISB-2001 | Phase 1 Clinical | Ichnos Sciences Sa | Multiple Myeloma | Details |
| OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | Zhejiang University, OriCell Therapeutics Co Ltd | Multiple Myeloma | Details |
| HY-027 | HY-027 | Phase 1 Clinical | Juventas Cell Therapy Ltd | Multiple Myeloma | Details |
| MEDI-2228 | MEDI-2228 | Phase 1 Clinical | Medimmune Llc | Multiple Myeloma | Details |
| IBI-346 | IBI-346 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Multiple Myeloma | Details |
| BCMA-NKE | BCMA-NKE | Phase 1 Clinical | Bristol-Myers Squibb Company | Multiple Myeloma | Details |
| KJ-C2111 | KJ-C2111; CT-0590 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| MCM-998 | MCM-998; LXG-250 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
| BCMA-UCART cell therapy (Shanghai Bioray Laboratory) | Phase 1 Clinical | BRL Medicine Inc | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis; Multiple Myeloma; Multiple Sclerosis; Neuromyelitis Optica | Details | |
| ALLO-605 | ALLO-605; ALLO605 | Phase 1 Clinical | Cellectis Sa, Overland Pharmaceuticals (Shanghai) Co Ltd | Multiple Myeloma | Details |
| AUTO-8 | AUTO-8; AUTO8 | Phase 1 Clinical | Autolus Therapeutics Plc, University College London | Multiple Myeloma | Details |
| CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Multiple Myeloma | Details | |
| JWCAR129 | JWCAR129; JWCAR-129 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Multiple Myeloma | Details |
| Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) | Phase 1 Clinical | Chongqing Xinqiao Hospital | Multiple Myeloma | Details | |
| BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) | LCAR-BCX | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Multiple Myeloma | Details |
| CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University, Shanghai YaKe Biotechnology Co Ltd | Nephritis; Scleroderma, Systemic; Autoimmune Diseases; Sjogren's Syndrome; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
| C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Multiple Myeloma | Details | |
| Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) | Phase 1 Clinical | Persongen Biotherapeutics | Multiple Myeloma | Details | |
| BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Multiple Myeloma | Details | |
| CC-98633 | CC-98633 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
| Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Hematologic Neoplasms | Details | |
| Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Multiple Myeloma | Details | |
| SA-102 | SA-102; SA102 | Clinical | Wuhan Si'an Medical Technology Co Ltd | Multiple Myeloma | Details |
| Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics) | ACT-001(Acellytron Therapeutics) | Clinical | Acellytron Therapeutics | Multiple Myeloma | Details |
| Anti-BCMA chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics) | Clinical | Multiple Myeloma | Details | ||
| PD-1Ab21-BCMACAR-T (CD biopharma) | CD-003; CD-203 | Clinical | Multiple Myeloma | Details | |
| BCMA targeting UCAR-T cell therapy (PersonGen BioTherapeutics) | UTAA17 | Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Multiple Myeloma | Details |
| CT-0590(The First Affiliated Hospital Of Soochow University) | CT-0590 | Clinical | CARsgen Therapeutics Holdings Ltd | Multiple Myeloma | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Belantamab mafodotin | GSK-2857916; GSK2857916 | Approved | Glaxosmithkline Plc | BLENREP | Mainland China(BOAO LECHENG) | Multiple Myeloma | Glaxosmithkline Plc | 2020-08-05 | Bone Marrow Neoplasms; Lymphoma, B-Cell; Hematologic Diseases; Paraproteinemias; Immunoglobulin Light-chain Amyloidosis; Plasmacytoma; Corneal Diseases; Neoplasms; Blood Protein Disorders; Multiple Myeloma; Plasmablastic Lymphoma; Neoplasms, Plasma Cell; Amyloidosis | Details |
| Idecabtagene vicleucel | bb-2121 | Approved | Bluebird Bio Inc | Abecma | United States | Multiple Myeloma | Celgene Corp | 2021-03-26 | Multiple Myeloma | Details |
| Zevorcabtagene Autoleucel | CT-053-CARsgen | Approved | Carsgen Biomedicine (Shanghai) Co Ltd | 赛恺泽 | Mainland China | Multiple Myeloma | Kaixing Life Technology (Shanghai) Co Ltd | 2024-02-23 | Multiple Myeloma | Details |
| Equecabtagene Autoleucel | CT-103A; CT103A; IBI-326 | Approved | Nanjing Iaso Biotherapeutics Co Ltd, Innovent Biologics(Suzhou) Co Ltd | 福可苏, FUCASO | Mainland China | Multiple Myeloma | Nanjing Xunlu Biomedicine Co Ltd | 2023-06-30 | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis; Myositis; Autoimmune Diseases; Multiple Myeloma; Multiple Sclerosis; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Autoimmune Diseases of the Nervous System; POEMS Syndrome; Encephalitis | Details |
| Teclistamab | JNJ-64007957; JNJ-64007959; JNJ-7957 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | TECAYLI, TECVAYLI, 泰立珂 | EU | Multiple Myeloma | Janssen-Cilag International Nv | 2022-08-23 | Hematologic Diseases; Immunoglobulin Light-chain Amyloidosis; Smoldering Multiple Myeloma; Multiple Myeloma | Details |
| Ciltacabtagene autoleucel | JNJ-4528; LCAR-B38M; JNJ-68284528 | Approved | Nanjing Legend Biotechnology Co Ltd | Carvykti, 卡卫荻 | United States | Multiple Myeloma | Nanjing Legend Biotechnology Co Ltd, Janssen Research & Development Llc | 2022-02-28 | Multiple Myeloma | Details |
| Elranatamab | PF-06863135; PF‑3135; RN-613 | Approved | Pfizer Inc | Elrexfio, ELREXFIO, ELREXFIO™ | United States | Multiple Myeloma | Pfizer Inc | 2023-08-14 | Bone Marrow Neoplasms; Smoldering Multiple Myeloma; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma | Details |
Product Reviews
W***A2025-11-07
0People LikeUsed this recombinant protein in the CD2 target nanobody R&D project. The protein activity is good, the early animal immunization and screening work progressed smoothly. Recently started ELISA activity detection of expressed antibody recombinant protein, the antibody molecule EC50 is ideal.- S***i2025-11-04 0People LikeWe have repurchased this item dozens of time. This product is very effective for flow cytometry and we use it to help detect our BCMA CAR-T product.
- S***i2025-10-29 0People LikeWe have repurchased this item dozens of time. This product is very effective for flow cytometry and we use it to help detect our BCMA CAR-T product.
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved